Trial · NCT00585195
Participant flow84
How many started, completed or left each group, period by period.
1 to 20 of 84
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Low Dose Escalation Cohort: Crizotinib 50 mg QD | 3 | |
| Overall Study | STARTED | Low Dose Escalation Cohort: Crizotinib 100 mg QD | 4 | |
| Overall Study | STARTED | Low Dose Escalation Cohort: Crizotinib 200 mg QD | 9 | |
| Overall Study | STARTED | Low Dose Escalation Cohort: Crizotinib 200 mg BID | 7 | |
| Overall Study | STARTED | Low Dose Escalation Cohort: Crizotinib 250 mg BID | 9 | |
| Overall Study | STARTED | Low Dose Escalation Cohort: Crizotinib 300 mg BID | 6 | |
| Overall Study | STARTED | High Dose Escalation Cohort: Crizotinib 300 mg QD | 7 | |
| Overall Study | STARTED | High Dose Escalation Cohort: Crizotinib 400 mg QD | 5 | |
| Overall Study | STARTED | High Dose Escalation Cohort: Crizotinib 500 mg QD | 3 | |
| Overall Study | STARTED | High Dose Escalation Cohort: Crizotinib 650 mg QD | 6 | |
| Overall Study | STARTED | High Dose Escalation Cohort: Crizotinib 800 mg QD | 11 | |
| Overall Study | STARTED | RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg | 53 | |
| Overall Study | STARTED | RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg | 85 | |
| Overall Study | STARTED | RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg | 41 | |
| Overall Study | STARTED | RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg | 48 | |
| Overall Study | STARTED | RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg | 19 | |
| Overall Study | STARTED | RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg | 154 | |
| Overall Study | STARTED | RP2D Cohort: Enriched Other: Crizotinib 250 mg | 67 | |
| Overall Study | STARTED | RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole | 21 | |
| Overall Study | STARTED | RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg +Rifampin | 18 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00585195/flow